Map To FDA RiskMAPs
This article was originally published in RPM Report
Executive Summary
Increased public scrutiny of drug safety is making risk management plans de rigeur for many new chemical entities and marketed products with definable adverse effects. FDA is using a system of special review teams to determine which plans pass muster.
You may also be interested in...
FDA's Drug Safety Changes: Safe Legislation; Unsafe Climate
The message from RPM's FDA/CMS Summit Conference: if you want to handicap the effect of the continuing drug safety debate around FDA, you can track the progress of the Kennedy-Enzi bill through Congress - and listen to the tone of the comments from the agency's top managers and its critics. Both will tell you what's at stake for pharma in 2007.
Time to Pay the Piper? Industry Prepares for a Fight Over User Fees
The pharmaceutical industry and FDA are getting ready for a fight-and for once they are on the same side. They want Congress to reauthorize the Prescription Drug User Fee Act quickly and cleanly-without tacking on other reforms to FDA's drug regulations. They probably won't get their wish.
Time to Pay the Piper? Industry Prepares for a Fight Over User Fees
The pharmaceutical industry and FDA are getting ready for a fight-and for once they are on the same side. They want Congress to reauthorize the Prescription Drug User Fee Act quickly and cleanly-without tacking on other reforms to FDA's drug regulations. They probably won't get their wish.